Cargando…
Viral based vaccine TG4010 induces broadening of specific immune response and improves outcome in advanced NSCLC
BACKGROUND: Advanced non-small cell lung cancer patients receiving TG4010, a therapeutic viral vaccine encoding human Mucin 1 and interleukin-2 in addition to standard chemotherapy, displayed longer overall survival in comparison to that of patients treated with standard chemotherapy alone. Our stud...
Autores principales: | Tosch, Caroline, Bastien, Bérangère, Barraud, Luc, Grellier, Benoit, Nourtier, Virginie, Gantzer, Murielle, Limacher, Jean Marc, Quemeneur, Eric, Bendjama, Kaïdre, Préville, Xavier |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5604422/ https://www.ncbi.nlm.nih.gov/pubmed/28923084 http://dx.doi.org/10.1186/s40425-017-0274-x |
Ejemplares similares
-
Sequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: Preclinical studies with MVA-βGal and MVA-MUC1 (TG4010) in a murine tumor model
por: Remy-Ziller, Christelle, et al.
Publicado: (2017) -
TG4010: A therapeutic vaccine against MUC1 expressing tumors
por: Limacher, Jean-Marc, et al.
Publicado: (2012) -
Impact of TG4010 Vaccine on Health-Related Quality of Life in Advanced Non-Small-Cell Lung Cancer: Results of a Phase IIB Clinical Trial
por: Rotonda, Christine, et al.
Publicado: (2015) -
Safety studies and viral shedding of intramuscular administration of oncolytic vaccinia virus TG6002 in healthy beagle dogs
por: Béguin, Jérémy, et al.
Publicado: (2020) -
TG4010 immunotherapy plus chemotherapy as first-line treatment of advanced non small cell lung cancer (NSCLC): Phase IIb results of the TIME trial
por: Nemunaitis, John, et al.
Publicado: (2015)